

## ASCO GU 2019 Trials on non clear cell Renal Cell Carcinoma

Trial	RCC Type	Trial Size	Overall Response Rate %	Complete Response %	Partial Response %	Stable Disease %	Progressive Disease %
<b>KEYNOTE 427</b> First Line Pembrolizumab (PD-L1 inhibitor)	Papillary	118	25.4	4.2	21.2	34.7	33.9
	Chromophobe	21	9.6	4.8	4.8	47.6	42.9
	Unclassified	26	34.6	7.7	26.9	7.7	46.2
<b>CALYPSO</b> savolitinib (MET inhibitor) and durvalumab (PD-L1 inhibitor)	Papillary	41	27	0	27	39	27